MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
MorphoSys AG has announced that its licensing partner, Centocor R&D Inc., has enrolled a patient in a Phase 2 clinical trial with a HuCAL-derived fully human antibody. A Phase 1 clinical trial using the same antibody in oncology patients was initiated in 2007 and is ongoing.
The new trial is in an immunology indication. This achievement marks the first antibody, developed with MorphoSys's core technology, to enter human clinical trials in a second indication with partners. The initiation of the Phase 2 trial and the IND in a new indication trigger clinical milestone payments to MorphoSys.
